ArticleMolecular nutrition & food research2025
Dietary Consumption of Type 2 Resistant Starch and d-Fagomine Delays Progression of Metabolic Disturbances in Male Rats on High-Fat Diet.
Article in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dietary Consumption of Type 2 Resistant Starch and d-Fagomine Delays Progression of Metabolic Disturbances in Male Rats on High-Fat Diet.Molecular nutrition & food research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
High-fat (HF) diets contribute to obesity, insulin resistance, fatty liver, gut microbiota dysbiosis, oxidative stress, and low-grade chronic inflammation. This study evaluated the preventive effects of dietary Type 2 resistant starch (RS2) from high-amylose maize and low-dose d-fagomine (FG) from buckwheat on these metabolic disturbances. Male Wistar-Kyoto rats (9-10 weeks old) were assigned to four diet groups for 10 weeks: standard (STD) diet, HF diet (45% kcal from fat), HF + RS diet (15% RS2), and HF + FG diet (0.1% FG). Body characteristics, metabolic parameters, oxidative stress, gut microbiota, short-chain fatty acids (SCFAs), and eicosanoids were analyzed. Both HF + RS and HF + FG diets reduced perigonadal fat, plasma triacylglycerols, and oxidative stress. HF + RS diet improved glucose tolerance without significantly affecting insulin sensitivity, while HF + FG diet showed a tendency for improvement at later stages. Additionally, HF + RS diet showed greater beneficial effects on body weight and liver steatosis than HF + FG diet, likely due to gut microbiota and SCFA modulation. RS2 exerted stronger metabolic effects than FG under HF diet conditions, suggesting its greater potential in mitigating obesity-related complications. FG effects may require longer exposure to manifest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.